Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial

Fontein, D.B.Y.; Houtsma, D.; Nortier, J.W.R.; Baak-Pablo, R.F.; Kranenbarg, E.M.K.; Straaten, T.R.J.H.M. van der; ... ; Guchelaar, H.J. (2014)

Article / Letter to editor

• Breast cancer
• Cyp19
• Exemestane
• Aromatase inhibitors
• Adverse events
• Pharmacogenetics
• Pharmacotherapy

• All authors: Fontein, D.B.Y.; Houtsma, D.; Nortier, J.W.R.; Baak-Pablo, R.F.; Kranenbarg, E.M.K.; Straaten, T.R.J.H.M. van der; Putter, H.; Seynaeve, C.; Gelderblom, H.; Velde, C.J.H. van de; Guchelaar, H.J.
• Date: 2014-04-30
• Journal: Breast Cancer Research and Treatment
• Volume: 144
• Issue: 3
• Pages: 599 - 606
• DOI: doi:10.1007/s10549-014-2873-2